Eli Lilly & Co. (LLY) reports tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity
Go back to Eli Lilly & Co. (LLY) reports tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1152.93 +0.49 (0.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1152.44 | 52 Week High | $88.16 | |||
| Open | $1150.00 | 52 Week Low | $67.88 | |||
| Day High | $1157.60 | P/E | 266.88 | |||
| Day Low | $1140.27 | EPS | $4.32 | |||
| Volume | 4,549,709 | |||||
